Opus Genetics, Inc. ("Opus” or the "Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing ...

Warrants to be issued as part of the public offering and concurrent private placement could bring in up to $21.4 million of additional capital 30 days following the release of OPGx-BEST1 DUO-1001 ...

Opus Genetics announces $20 million public offering and $1.5 million private placement for gene therapy development and operations. Opus Genetics, Inc., a clinical-stage biotechnology company ...

The Philippines Stock Exchange Inc. (PSE) recently announced that big companies planning to be listed in the Philippine stock ...

The Securities and Exchange Commission (SEC) has approved a proposal by the Philippine Stock Exchange (PSE) to exempt giant ...

On March 12, 2025, the staff of the Division of Corporate Finance (the staff) of the US Securities and Exchange Commission (the SEC) ...

Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole o ...

Mumbai: The proposed initial public offerings (IPOs) of two large non-banking financial ... Also, such firms cannot sell ...

The Philippine Stock Exchange Inc. (PSE) has relaxed the minimum public float requirement for large offerings in a bid to ...

This approval includes provisions to pursue capital raises through multiple avenues, including public offerings, private placements, and rights issues, in both Nigerian and international capital ...